BRPI1006418A2 - suspensões aquosas de riluzol - Google Patents

suspensões aquosas de riluzol

Info

Publication number
BRPI1006418A2
BRPI1006418A2 BRPI1006418A BRPI1006418A BRPI1006418A2 BR PI1006418 A2 BRPI1006418 A2 BR PI1006418A2 BR PI1006418 A BRPI1006418 A BR PI1006418A BR PI1006418 A BRPI1006418 A BR PI1006418A BR PI1006418 A2 BRPI1006418 A2 BR PI1006418A2
Authority
BR
Brazil
Prior art keywords
riluzole
aqueous suspensions
suspensions
aqueous
Prior art date
Application number
BRPI1006418A
Other languages
English (en)
Inventor
Daniele Barbareschi
Jaime Moscoso
Marco Adami
Paolo Mascagni
Roberta Artico
Tiziano Oldoni
Original Assignee
Italfarmaco Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40810549&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1006418(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Italfarmaco Spa filed Critical Italfarmaco Spa
Publication of BRPI1006418A2 publication Critical patent/BRPI1006418A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/428Thiazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI1006418A 2009-03-13 2010-03-02 suspensões aquosas de riluzol BRPI1006418A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09425101A EP2228054A1 (en) 2009-03-13 2009-03-13 Riluzole aqueous suspensions
PCT/EP2010/052598 WO2010102923A2 (en) 2009-03-13 2010-03-02 Riluzole aqueous suspensions

Publications (1)

Publication Number Publication Date
BRPI1006418A2 true BRPI1006418A2 (pt) 2016-11-29

Family

ID=40810549

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1006418A BRPI1006418A2 (pt) 2009-03-13 2010-03-02 suspensões aquosas de riluzol

Country Status (21)

Country Link
US (1) US8765150B2 (pt)
EP (2) EP2228054A1 (pt)
JP (1) JP5607083B2 (pt)
KR (1) KR101680175B1 (pt)
CN (1) CN102341091B (pt)
BR (1) BRPI1006418A2 (pt)
CA (1) CA2748856C (pt)
CL (1) CL2011002217A1 (pt)
CO (1) CO6410281A2 (pt)
CY (1) CY1113825T1 (pt)
DK (1) DK2405890T3 (pt)
ES (1) ES2400349T3 (pt)
HR (1) HRP20130021T1 (pt)
MX (1) MX2011008922A (pt)
PE (1) PE20120649A1 (pt)
PL (1) PL2405890T3 (pt)
PT (1) PT2405890E (pt)
RU (1) RU2498802C2 (pt)
SI (1) SI2405890T1 (pt)
SM (1) SMT201300022B (pt)
WO (1) WO2010102923A2 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014000742A2 (pt) * 2011-07-13 2016-08-23 Andrew A Wolff terapia de combinação de als
US10357497B2 (en) * 2012-06-23 2019-07-23 Biohaven Pharmaceutical Holding Company Limited Pro-drugs of riluzole and their method of use for the treatment of amyotrophic lateral sclerosis
EP3023093B1 (en) * 2014-11-20 2017-07-26 S.I.I.T. S.r.l.-Servizio Internazionale Imballaggi Termosaldanti Medicinal preparation based on diosmectite
CN107735077A (zh) * 2014-11-21 2018-02-23 拜尔哈文制药股份有限公司 利鲁唑的舌下给药
WO2016081472A1 (en) * 2014-11-21 2016-05-26 Biohaven Pharmaceutical Holding Company Ltd. Sublingual formulation of riluzole
US11911369B2 (en) * 2015-03-03 2024-02-27 Biohaven Therapeutics Ltd. Prodrugs of riluzole and their method of use
ITUB20155193A1 (it) * 2015-11-03 2017-05-03 Italfarmaco Spa Sospensioni orali di Givinostat fisicamente e chimicamente stabili
CN105726477B (zh) * 2016-03-01 2018-10-12 山东司邦得制药有限公司 一种小儿多潘立酮混悬液及其制备方法
CN108721325B (zh) * 2017-04-13 2020-03-06 辽宁大熊制药有限公司 蒙脱石混悬液及其制备方法
WO2019108594A1 (en) * 2017-11-28 2019-06-06 University Of Houston System Liquid formulations of riluzole for oral and intravenous use
CN111437256A (zh) * 2019-01-17 2020-07-24 北京万全德众医药生物技术有限公司 一种利鲁唑缓释口服混悬液
CN115025056A (zh) * 2022-06-27 2022-09-09 郑州大学第一附属医院 一种含有替加氟、吉莫斯特和奥替拉西钾的口腔崩解制剂

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP249A (en) * 1990-04-24 1993-03-17 Biota Scient Management Pty Ltd Anti-viral compounds.
FR2688138B1 (fr) * 1992-03-06 1995-05-05 Rhone Poulenc Rorer Sa Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la sclerose laterale amyotrophique.
AUPN605795A0 (en) * 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
FR2777781B1 (fr) * 1998-04-24 2004-04-09 Rhone Poulenc Rorer Sa Associations riluzole et l-dopa pour le traitement de la maladie de parkinson
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
JP2003522121A (ja) * 1999-06-04 2003-07-22 フェレニヒング フォール クリステレイク ウェテンスハッペリキク オンデルウェイス 多発性硬化症の処置のためのリルゾールの使用
JP2003506464A (ja) 1999-08-12 2003-02-18 イーライ・リリー・アンド・カンパニー 外部寄生虫殺虫性の水性懸濁製剤
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6432992B1 (en) 2000-06-05 2002-08-13 Aventis Pharm Sa Use of riluzole or its salts for the prevention and treatment of adrenoleukodystrophy
US6613308B2 (en) * 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US6861413B2 (en) * 2001-05-22 2005-03-01 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
EP1492511B3 (fr) 2002-04-09 2012-05-02 Flamel Technologies Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
SI1567152T1 (sl) 2002-11-15 2013-10-30 Teva Pharmaceutical Industries Ltd. Uporaba rasagilina z riluzolom za zdravljenje amiotrofične lateralne skleroze
ATE337003T1 (de) 2003-04-28 2006-09-15 Biofrontera Bioscience Gmbh Verwendung von riluzole kombiniert mit geeigneten hilfs-und zusatzstoffen zur behandlung von krankheiten, die durch eine hyperproliferation von keratinozyten gekennzeichnet sind, insbesondere neurodermitis und psoriasis
US9492541B2 (en) 2004-09-14 2016-11-15 Sovereign Pharmaceuticals, Llc Phenylepherine containing dosage form
US20050266032A1 (en) 2003-12-17 2005-12-01 Sovereign Pharmaceuticals, Ltd. Dosage form containing multiple drugs
EP1778286A4 (en) 2004-03-03 2009-04-08 Teva Pharma COMBINATION THERAPY WITH ACETATE OF GLATIRAMER AND RILUZOLE
US7691368B2 (en) * 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
ITMI20061274A1 (it) 2006-06-30 2008-01-01 Consiglio Nazionale Ricerche Vettori nanoparticellari lipidici contenenti riluzolo e composizioni farmaceutiche che li contengono
US9132071B2 (en) * 2006-07-28 2015-09-15 Santen Sas Compositions containing quaternary ammonium compounds

Also Published As

Publication number Publication date
CN102341091B (zh) 2013-08-07
ES2400349T3 (es) 2013-04-09
RU2498802C2 (ru) 2013-11-20
CN102341091A (zh) 2012-02-01
DK2405890T3 (da) 2013-02-04
JP5607083B2 (ja) 2014-10-15
JP2012520254A (ja) 2012-09-06
EP2405890A2 (en) 2012-01-18
CY1113825T1 (el) 2016-07-27
EP2228054A1 (en) 2010-09-15
SI2405890T1 (sl) 2013-02-28
MX2011008922A (es) 2011-12-06
US20120039953A1 (en) 2012-02-16
HK1161985A1 (en) 2012-08-17
HRP20130021T1 (hr) 2013-02-28
KR101680175B1 (ko) 2016-11-28
SMT201300022B (it) 2013-03-08
US8765150B2 (en) 2014-07-01
CL2011002217A1 (es) 2012-03-09
WO2010102923A3 (en) 2011-03-03
PE20120649A1 (es) 2012-06-07
EP2405890B1 (en) 2012-11-28
KR20120003854A (ko) 2012-01-11
PL2405890T3 (pl) 2013-04-30
CO6410281A2 (es) 2012-03-30
PT2405890E (pt) 2013-02-20
CA2748856C (en) 2017-01-03
RU2011141422A (ru) 2013-04-20
WO2010102923A2 (en) 2010-09-16
CA2748856A1 (en) 2010-09-16

Similar Documents

Publication Publication Date Title
BRPI1006418A2 (pt) suspensões aquosas de riluzol
DK3617400T3 (da) Anvendelse af nanofibrillære cellulosesuspensioner
EP2485698A4 (en) WHEELCHAIR SUSPENSION
SMT201600075B (it) Composto di diamminocarbossammide eterociclica
PT3509341T (pt) Adaptação de parâmetros de transferência
EP2508671A4 (en) CELLULOSE NANO FIBERS
EP2419392A4 (en) perfluorocarbon emulsions
FI20095666A0 (fi) Hitsauksen optimointi
EP2641343A4 (en) CONFIGURATION OF A BUILDING
BRPI1006128A2 (pt) derivados de sulfonamida
DOP2012000114A (es) Inhibidor bromodominio de benzodiazepina
EP2442711A4 (en) DETERMINATION OF HEMODYNAMIC PERFORMANCE
EP2394844A4 (en) SEAT SUSPENSION
EP2418213A4 (en) NEURO MEDIN-U DERIVATIVE
BRPI1013235A2 (pt) suspensão de veículo
PL2493466T3 (pl) Nowe przeciwguzowe zastosowanie kabazytakselu
EP2429699A4 (en) DENSITY MODIFICATION
BRPI1008744A2 (pt) hidrotratamento de caboidratos
IT1398296B1 (it) Disposizione di sensori
SMT201600031B (it) Composti eterociclici di fenossimetile
PT2492266E (pt) Derivado de 5-hidroxipirimidino-4-carboxamida
DK2453858T3 (da) Fremgangsmåde
BR112012000654A2 (pt) estruturas de suspensao
EP2405804A4 (en) ISCHEMIC STATUS SURVEILLANCE
EP2397246A4 (en) COMPOSITE BODY

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/03/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.